Press
EpiVax Recieves $600,000 NIH Grant to Further Research in Type 1 Diabetes
Posted on September 29, 2008 by Admin EpivaxEpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop “Epi-13”, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a ...Read moreEpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference
Posted on January 25, 2008 by Admin EpivaxEpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...Read moreEpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference
Posted on January 25, 2008 by Annie De GrootEpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...Read moreEpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural “regulatory” T cells
Posted on October 25, 2007 by Admin EpivaxOctober 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...Read moreEpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural "regulatory" T cells
Posted on October 25, 2007 by Annie De GrootOctober 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...Read moreEpiVax awarded $590,000 SBIR for Immunoinformatics-driven TB Vaccine
Posted on September 25, 2007 by Admin EpivaxThe National Institutes of Health, National Institute Of Allergy And Infectious Diseases awarded a grant in the amount of $590,912 to EpiVax, Inc. in support of the development of a multi-epitope TB vaccine. This two-year award will allow EpiVax, to pursue pre-clinical studies leading to the optimization of its TB genome-derived DNA vaccine for the ...Read moreEpiVax Awarded a Grant for Hemophilia Therapy
Posted on July 25, 2007 by Admin EpivaxPROVIDENCE BUSINESS NEWS By David Ortiz A Providence-based biotechnology pharmaceutical firm that genetically engineers new vaccines has received a $528,313 grant to begin developing a novel treatment for hemophilia. EpiVax Inc. will use the grant, from the National Institutes of Health, to reengineer Factor VIII, a clotting agent in the blood that is deficient in hemophiliacs. ...Read moreEpiVax funded to advance research on a new, improved “Botox”
Posted on March 25, 2007 by Admin EpivaxFebruary 26, 2007 (Providence, RI)—- EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as ...Read moreEpiVax wins SBIR Phase I grant totaling $993,771 to Develop Smallpox Vaccine
Posted on June 15, 2005 by Admin EpivaxProvidence, RI, December 17, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the ...Read moreEpiVax Is Awarded H. Pylori SBIR Grant by National Institutes of Health
Posted on June 1, 2005 by Admin EpivaxPROVIDENCE, RI — 04/27/2005 — EpiVax, Inc., a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities and pharmaceutical companies, today announced that it was awarded a $600,000 Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The grant award ...Read moreEpiVax moves to new facility at 146 Clifford Street including office and laboratory space
Posted on November 25, 2004 by Admin EpivaxEpiVax moves to new facility at 146 Clifford Street including office and laboratory spaceRead moreEpiVax wins SBIR Phase I grant totaling $859,773 to Develop Tularemia Vaccine
Posted on September 1, 2004 by Admin EpivaxProvidence, RI, September 8, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National ...Read moreEpiVax signs Master Services Agreement with Amgen
Posted on July 25, 2004 by Admin EpivaxEpiVax signs Master Services Agreement with AmgenRead moreEpiVax renews technology license with Brown University
Posted on August 25, 2003 by Admin EpivaxEpiVax renews technology license with Brown UniversityRead moreEpiVax receives $150,000 in phase II funding from Slater Center for Bio-Technology
Posted on March 25, 2003 by Admin EpivaxEpiVax receives $150,000 in phase II funding from Slater Center for Bio-TechnologyRead more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.